Open Access
Executive summary: Japanese guidelines for adult asthma (JGL) 2021
Akio Niimi
1
,
Koichi Fukunaga
2
,
Masami TANIGUCHI
3
,
Yuki Nakamura
4
,
Etsuko Tagaya
5
,
Tomoya Horiguchi
6
,
Akihito Yokoyama
7
,
Masao Yamaguchi
8
,
Minaka Nagata
9, 10
3
Center for Immunology and Allergology, Shonan Kamakura General Hospital, Kanagawa, Japan
|
4
Medical Center for Allergic and Immune Diseases, Yokohama City Minato Red Cross Hospital, Yokohama, Japan
|
6
Department of Respiratory Medicine, Toyota Regional Medical Center, Toyota, Japan
|
Publication type: Journal Article
Publication date: 2023-04-01
scimago Q1
wos Q1
SJR: 1.627
CiteScore: 10.4
Impact factor: 6.7
ISSN: 13238930, 14401592
PubMed ID:
36959028
General Medicine
Immunology and Allergy
Abstract
Asthma is characterized by chronic airway inflammation, variable airway narrowing, and sensory nerve irritation, which manifest as wheezing, dyspnea, chest tightness, and cough. Longstanding asthma may result in airway remodeling and become intractable. Despite the increased prevalence of asthma in adults, asthma-associated deaths have decreased in Japan (0.94 per 100,000 people in 2020). The goals of asthma treatment include the control of symptoms and reduction of future risks. A functional partnership between physicians and patients is indispensable for achieving these goals. Long-term management with medications and the elimination of triggers and risk factors are fundamental to asthma treatment. Asthma is managed via four steps of pharmacotherapy ("controllers"), ranging from mild to intensive treatments, depending on disease severity; each step involves daily administration of an inhaled corticosteroid, which varies from low to high dosage. Long-acting β2 agonists, leukotriene receptor antagonists, sustained-release theophylline, and long-acting muscarinic antagonists are recommended as add-on drugs. Allergen immunotherapy is a new option that is employed as a controller treatment. Further, as of 2021, anti-IgE antibody, anti-IL-5 and anti-IL-5 receptor α-chain antibodies, and anti-IL-4 receptor α-chain antibodies are available for the treatment of severe asthma. Bronchial thermoplasty can be performed for asthma treatment, and its long-term efficacy has been reported. Algorithms for their usage have been revised. Comorbidities, such as allergic rhinitis, chronic rhinosinusitis, chronic obstructive pulmonary disease, and aspirin-exacerbated respiratory disease, should also be considered during the treatment of chronic asthma. Depending on the severity of episodes, inhaled short-acting β2 agonists, systemic corticosteroids, short-acting muscarinic antagonists, oxygen therapy, and other approaches are used as needed ("relievers") during exacerbation.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
6
7
|
|
|
Allergology International
7 publications, 14%
|
|
|
Respiratory Investigation
6 publications, 12%
|
|
|
Journal of Clinical Medicine
4 publications, 8%
|
|
|
Journal of Allergy and Clinical Immunology Global
3 publications, 6%
|
|
|
Journal of Asthma
2 publications, 4%
|
|
|
Annals of Allergy, Asthma and Immunology
2 publications, 4%
|
|
|
Respiratory Physiology and Neurobiology
1 publication, 2%
|
|
|
The Lancet Respiratory Medicine
1 publication, 2%
|
|
|
Journal of Ethnopharmacology
1 publication, 2%
|
|
|
Expert Opinion on Pharmacotherapy
1 publication, 2%
|
|
|
Journal of Asthma and Allergy
1 publication, 2%
|
|
|
Respiratory Research
1 publication, 2%
|
|
|
BMC Pulmonary Medicine
1 publication, 2%
|
|
|
Journal of Functional Foods
1 publication, 2%
|
|
|
Internal and Emergency Medicine
1 publication, 2%
|
|
|
npj Primary Care Respiratory Medicine
1 publication, 2%
|
|
|
Phytomedicine
1 publication, 2%
|
|
|
Heliyon
1 publication, 2%
|
|
|
Allergy, Asthma and Immunology Research
1 publication, 2%
|
|
|
Journal of Allergy and Clinical Immunology
1 publication, 2%
|
|
|
Advances in Therapy
1 publication, 2%
|
|
|
Respiratory Medicine
1 publication, 2%
|
|
|
Pulmonary Therapy
1 publication, 2%
|
|
|
Yakugaku Zasshi
1 publication, 2%
|
|
|
Journal of Allergy and Clinical Immunology: In Practice
1 publication, 2%
|
|
|
Critical Reviews in Toxicology
1 publication, 2%
|
|
|
Clinical and Experimental Allergy
1 publication, 2%
|
|
|
Respiratory Medicine and Research
1 publication, 2%
|
|
|
Journal of Thoracic Disease
1 publication, 2%
|
|
|
1
2
3
4
5
6
7
|
Publishers
|
5
10
15
20
25
30
|
|
|
Elsevier
29 publications, 58%
|
|
|
Springer Nature
6 publications, 12%
|
|
|
Taylor & Francis
5 publications, 10%
|
|
|
MDPI
4 publications, 8%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 2%
|
|
|
Soonchunhyang University
1 publication, 2%
|
|
|
Pharmaceutical Society of Japan
1 publication, 2%
|
|
|
Wiley
1 publication, 2%
|
|
|
AME Publishing Company
1 publication, 2%
|
|
|
5
10
15
20
25
30
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
50
Total citations:
50
Citations from 2024:
46
(92%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Niimi A. et al. Executive summary: Japanese guidelines for adult asthma (JGL) 2021 // Allergology International. 2023. Vol. 72. No. 2. pp. 207-226.
GOST all authors (up to 50)
Copy
Niimi A., Fukunaga K., TANIGUCHI M., Nakamura Y., Tagaya E., Horiguchi T., Yokoyama A., Yamaguchi M., Nagata M. Executive summary: Japanese guidelines for adult asthma (JGL) 2021 // Allergology International. 2023. Vol. 72. No. 2. pp. 207-226.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.alit.2023.02.006
UR - https://doi.org/10.1016/j.alit.2023.02.006
TI - Executive summary: Japanese guidelines for adult asthma (JGL) 2021
T2 - Allergology International
AU - Niimi, Akio
AU - Fukunaga, Koichi
AU - TANIGUCHI, Masami
AU - Nakamura, Yuki
AU - Tagaya, Etsuko
AU - Horiguchi, Tomoya
AU - Yokoyama, Akihito
AU - Yamaguchi, Masao
AU - Nagata, Minaka
PY - 2023
DA - 2023/04/01
PB - Elsevier
SP - 207-226
IS - 2
VL - 72
PMID - 36959028
SN - 1323-8930
SN - 1440-1592
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2023_Niimi,
author = {Akio Niimi and Koichi Fukunaga and Masami TANIGUCHI and Yuki Nakamura and Etsuko Tagaya and Tomoya Horiguchi and Akihito Yokoyama and Masao Yamaguchi and Minaka Nagata},
title = {Executive summary: Japanese guidelines for adult asthma (JGL) 2021},
journal = {Allergology International},
year = {2023},
volume = {72},
publisher = {Elsevier},
month = {apr},
url = {https://doi.org/10.1016/j.alit.2023.02.006},
number = {2},
pages = {207--226},
doi = {10.1016/j.alit.2023.02.006}
}
Cite this
MLA
Copy
Niimi, Akio, et al. “Executive summary: Japanese guidelines for adult asthma (JGL) 2021.” Allergology International, vol. 72, no. 2, Apr. 2023, pp. 207-226. https://doi.org/10.1016/j.alit.2023.02.006.